Clinical Trials Monitor

Section edited by Leisha A. Emens, MD, PhD

Reports on important new trial results; updates on new drug approvals and ongoing clinical studies; key perspectives on clinical issues and advances in the field relevant to the everyday use of cancer immunotherapy in the clinic. This section also aims to address trial design and analysis considerations that may be unique to cancer immunotherapy, and to provide guidance for implementing and managing the use of cancer immunotherapies in the clinic.

  1. Clinical Trials Monitor

    PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?

    Research in cancer immunology is currently accelerating following a series of cancer immunotherapy breakthroughs during the last 5 years. Various monoclonal antibodies which block the interaction between check...

    Claud Grigg and Naiyer A. Rizvi

    Journal for ImmunoTherapy of Cancer 2016 4:48

    Published on: 16 August 2016

  2. Clinical trials monitor

    Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine

    Because the benefits of immune checkpoint blockade may be restricted to tumors with pre-existing immune recognition, novel therapies that facilitate de novo immune activation are needed. DRibbles is a novel multi...

    David B. Page, Tyler W. Hulett, Traci L. Hilton, Hong-Ming Hu, Walter J. Urba and Bernard A. Fox

    Journal for ImmunoTherapy of Cancer 2016 4:25

    Published on: 17 May 2016

JITC logo

Advertisement